MX2020009813A - Composiciones y metodos para tratar el prurito. - Google Patents
Composiciones y metodos para tratar el prurito.Info
- Publication number
- MX2020009813A MX2020009813A MX2020009813A MX2020009813A MX2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating pruritus
- pruritus
- treating
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- -1 Sebacoyl Dinalbuphine Ester Chemical class 0.000 abstract 1
- ALOIOAGKUOQNID-ITCIXCFHSA-N bis[(4r,4as,7s,7ar,12bs)-3-(cyclobutylmethyl)-4a,7-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-9-yl] decanedioate Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC[C@@H]5O)O)CC1)OC(=O)CCCCCCCCC(=O)OC1=CC=C2C[C@@H]3[C@]4(O)CC[C@@H]([C@@H]5OC1=C2[C@]45CCN3CC1CCC1)O)CC1CCC1 ALOIOAGKUOQNID-ITCIXCFHSA-N 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650108P | 2018-03-29 | 2018-03-29 | |
| PCT/US2019/024706 WO2019191511A1 (en) | 2018-03-29 | 2019-03-28 | Compositions and methods for treating pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009813A true MX2020009813A (es) | 2020-11-11 |
Family
ID=68054657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009813A MX2020009813A (es) | 2018-03-29 | 2019-03-28 | Composiciones y metodos para tratar el prurito. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190298702A1 (enExample) |
| EP (1) | EP3755328A4 (enExample) |
| JP (1) | JP2021525225A (enExample) |
| KR (1) | KR20200138730A (enExample) |
| CN (1) | CN112040948A (enExample) |
| AU (1) | AU2019243571A1 (enExample) |
| BR (1) | BR112020019094A2 (enExample) |
| CA (1) | CA3094710A1 (enExample) |
| IL (1) | IL277463A (enExample) |
| MX (1) | MX2020009813A (enExample) |
| RU (1) | RU2020130919A (enExample) |
| TW (1) | TWI729371B (enExample) |
| WO (1) | WO2019191511A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121401263A (zh) * | 2020-02-14 | 2026-01-27 | 帝国制药美国公司 | 外用纳洛酮组合物及其使用方法 |
| CN113797167B (zh) * | 2020-06-16 | 2024-05-10 | 苏州恩华生物医药科技有限公司 | 一种塞纳布啡的储库制剂 |
| IL298929A (en) * | 2020-06-30 | 2023-02-01 | Dermira Inc | IRAK4 inhibitors and their topical uses |
| WO2022175973A1 (en) * | 2021-02-18 | 2022-08-25 | Navin Saxena Research And Technology Private Limited | An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130759C (enExample) * | 1965-10-07 | |||
| US5229130A (en) * | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
| US6503944B1 (en) * | 1999-05-26 | 2003-01-07 | The Andrew Jergens Company | Anhydrous skin care composition |
| US6967023B1 (en) * | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| ES2188481T3 (es) * | 2000-04-27 | 2003-07-01 | Oliver Yoa-Pu Hu | Derivados de polinalbufina. |
| US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
| US20070093517A1 (en) * | 2005-10-24 | 2007-04-26 | Gary Newton | Local anesthetic compositions |
| RU2596488C2 (ru) * | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| JP6247223B2 (ja) * | 2011-12-08 | 2017-12-13 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 化合物を投与するための局所用製剤 |
| US20140112957A1 (en) * | 2012-10-19 | 2014-04-24 | Oliver Yao-Pu Hu | Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form |
| WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| JP6935393B2 (ja) * | 2015-05-28 | 2021-09-15 | ルモサ セラピューティクス カンパニー， リミテッド | セバコイルジナルブフィンエステルの徐放のための医薬製剤 |
-
2019
- 2019-03-28 KR KR1020207027179A patent/KR20200138730A/ko not_active Ceased
- 2019-03-28 AU AU2019243571A patent/AU2019243571A1/en not_active Abandoned
- 2019-03-28 CA CA3094710A patent/CA3094710A1/en not_active Abandoned
- 2019-03-28 MX MX2020009813A patent/MX2020009813A/es unknown
- 2019-03-28 JP JP2020551516A patent/JP2021525225A/ja active Pending
- 2019-03-28 WO PCT/US2019/024706 patent/WO2019191511A1/en not_active Ceased
- 2019-03-28 US US16/368,609 patent/US20190298702A1/en not_active Abandoned
- 2019-03-28 RU RU2020130919A patent/RU2020130919A/ru unknown
- 2019-03-28 CN CN201980023503.1A patent/CN112040948A/zh active Pending
- 2019-03-28 TW TW108111046A patent/TWI729371B/zh not_active IP Right Cessation
- 2019-03-28 BR BR112020019094-2A patent/BR112020019094A2/pt not_active Application Discontinuation
- 2019-03-28 EP EP19776964.9A patent/EP3755328A4/en not_active Withdrawn
-
2020
- 2020-09-21 IL IL277463A patent/IL277463A/en unknown
-
2022
- 2022-04-29 US US17/661,444 patent/US20220362226A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019243571A1 (en) | 2020-10-15 |
| EP3755328A4 (en) | 2021-11-10 |
| EP3755328A1 (en) | 2020-12-30 |
| TW202002977A (zh) | 2020-01-16 |
| RU2020130919A3 (enExample) | 2022-04-29 |
| CN112040948A (zh) | 2020-12-04 |
| CA3094710A1 (en) | 2019-10-03 |
| TWI729371B (zh) | 2021-06-01 |
| US20190298702A1 (en) | 2019-10-03 |
| RU2020130919A (ru) | 2022-04-29 |
| KR20200138730A (ko) | 2020-12-10 |
| BR112020019094A2 (pt) | 2020-12-29 |
| JP2021525225A (ja) | 2021-09-24 |
| WO2019191511A1 (en) | 2019-10-03 |
| US20220362226A1 (en) | 2022-11-17 |
| IL277463A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX378145B (es) | Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias | |
| MX2023002507A (es) | Inhibidores de cd73. | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| HK1258098A1 (zh) | 治疗癌症的方法 | |
| EA033395B1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
| ZA202204941B (en) | Cd73 inhibitors | |
| JOP20190262B1 (ar) | مثبطات بيرازول magl | |
| MX2015011374A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| PH12020551728A1 (en) | Stat3 inhibitors | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| EP4650000A3 (en) | High concentration formulation | |
| WO2019224790A3 (en) | Prodrugs of fulvestrant | |
| MX2021010252A (es) | Inhibidores del receptor de glucocorticoides. | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). |